
Challenges and Opportunities in the Analysis of Live Microorganisms

Jean Schoeni, Ph.D., | October 6, 2022



Emerging Technologies



- ▶ The production of beneficial health effects are restricted to certain strains of live microorganisms
 - These abilities are not found across entire species or genera
- ▶ Beneficial strains must be administered in adequate amount to produce health benefits

▶ Quality Management:

Products have been found in the marketplace that do not meet label claim



- Mis-identified strains
- Labeled species or strains missing
- Species present but not on label
- Lower numbers than claimed

▶ Identification

- ▶ Correct to the strain level

▶ Enumeration

- ▶ Accurate strain counts

PROVIDE A WELL RECEIVED, COMMERCIALY VIABLE WAY TO IDENTIFY LIVE MICROORGANISMS TO THE STRAIN LEVEL

- ▶ FAO/WHO (2001) Probiotics in food: Health and nutritional properties and guidelines for evaluation
 - Suggests identification be made to the strain level by genetic typing
- ▶ USP General Chapter <64> Probiotic Testing
 - Many regulatory filings for commercial probiotics are made at the strain level
- ▶ Dronkers et al. (2020) Global analysis of clinical trials with probiotics
 - Complete strain identification given in only 49% of registered clinical trials

Phenotypic



Genomic

Hopes & Expectations

- ▶ Strain level identification
- ▶ Detect and identify minor populations
- ▶ Minimal rates
 - Mis-identification
 - Misinterpretation
 - Non-interpretable results
- ▶ Method does not need other methods to confirm results
- ▶ Little to no sample prep
- ▶ Sensitive, specific, accurate, reliable
- ▶ Rapid and cost effective

**PROVIDE A METHOD
THAT ACCURATELY
DETERMINES VIABLE
CELL COUNTS OF
EACH STRAIN OF LIVE
MICROORGANISM
PRESENT**

- ▶ FAO/WHO (2001), Probiotics in food: Health and nutritional properties and guidelines for evaluation
 - The label should state the viable concentration of each probiotic present at the end of shelf-life
- ▶ Hill et al. (2014), Consensus statement on scope and appropriate use of the term probiotic
 - If making health claim(s) there must be proof of efficacious dose delivery of viable strain(s) at end of shelf-life

Phenotypic




Genomic

Greatest Challenge: History

- ▶ Plating methods are considered “The Gold Standard” for live microorganism enumeration
 - Simple to apply
 - Low entry-level cost
 - Historical use
- ▶ The link between colony-forming units (CFU) and clinical data

Plating: Simple but Challenging

- ▶ Labor intensive
- ▶ Selecting appropriate sample and agar preparation
- ▶ Providing optimum growth requirements



- ▶ Methods lack robustness
- ▶ No reference standards
- ▶ Slow
 - Time to result can range from 2-7 days
- ▶ Variability in results
 - 20-30% or 10-15% RSD

Colony-Forming Units (CFU) & Clinical Data



▶ **Historic use of plating methods has led to a link between CFU & clinical data**

- Dosage is either not reported or is not reported as a CFU dosage in ~ 60% of published or registered trials
 - Zuccotti et al. (2008)
 - Probiotic clinical trials published from 1978-2007 found through searching PubMed and EMBASE
 - 74 of 201 (37%) studies report CFU dosage
 - Dronkers et al. (2020)
 - Globally registered probiotic trials from 2000-2019
 - 680 of 1,619 (42%) studies report CFU dosage



Technology & Innovation

- ▶ Develop technologies/methods to allow strain level counting
- ▶ Strive for simultaneous identification and enumeration

Addressing History

- ▶ Continue the conversation
 - Involve all stakeholders

- ▶ Technologies emerge to address questions and challenges
 - Challenges and opportunities for emerging technologies become cyclic
- ▶ Currently, new and additional tools (emerging technologies) are needed to meet strain expectations for identification and enumeration
- ▶ Emerging technologies may hold the key to improving overall quality management and quality of live microorganism products

Symposium Goals



- ▶ Explore the use of emerging technologies as potential paths to addressing challenges encountered when analyzing probiotics, live biotherapeutic products, and microbiomes.
- ▶ For a small selection of emerging technologies:
 - Enhance understanding of the theories driving the science
 - Look at performance
 - Give examples of current and potential uses/applications
- ▶ Provide a platform where you can freely ask questions and exchange ideas

Thank You

Enjoy the Symposium



The standard of trust

Stay Connected

Jean Schoeni | JeanSchoeni@EurofinsUS.com



The standard of trust